Show
Sort by
-
Drug holidays from bisphosphonates and denosumab in postmenopausal osteoporosis : EMAS position statement
-
Bisphosphonates or denosumab discontinuation and risk of fractures : response to the letter by Anastasilakis et al.
-
EMAS position statement: Testosterone replacement therapy in the aging male
-
EMAS position statement: Non-hormonal management of menopausal vasomotor symptoms
-
Non-hormonal management of menopausal vasomotor symptoms: psychosocial interventions
-
EMAS position statement: fertility preservation
-
EMAS position statement: Late parenthood
-
Management of epistaxis in hereditary hemorrhagic telangiectasia by Nd:YAG laser and quality of life assessment using the HR-QoL questionnaire